Outcome of patients with a rare type of astrocytoma is worse than expected: Study
Gliomas are a tumor that originate in the glial cells that surround neurons in the brain. Under the microscope, gliomas can be divided into several types based on the type of cells they invade. These include astrocytomas, which, as their name suggests, infect astrocytes, an important type of neuron.
A team of researchers from the Nagoya University Graduate School of Medicine has reported that patients with a rare form of brain and spinal cord cancer, localized isocitrate dehydrogenase wild-type (IDHwt) histologically diffuse astrocytoma, have a poor prognosis similar to the most malignant types of brain and spinal cord tumors. Their findings, published in the journal Scientific Reports, point to the need for strong postoperative care for patients with this type of tumor.
In 2016, to improve prognosis and patient management, the WHO classification of central nervous system tumors included a new classification of ‘diffuse gliomas’, based on the presence or absence of specific mutations. Two rare types of diffuse astrocytomas are infiltrative and localized isocitrate dehydrogenase wild-type (IDHwt) diffuse astrocytomas. Since they are so rare, there is a lack of information on whether the infiltrative or localized characteristics affect their prognosis and what this means for the patient.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.